Beta Amyloid

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2215 DAPT (GSI-IX) <1 mg/mL 86 mg/mL 50 mg/mL
S1575 RO4929097 <1 mg/mL 93 mg/mL 16 mg/mL
S2660 MK-0752 <1 mg/mL 89 mg/mL 45 mg/mL
S1262 Avagacestat (BMS-708163) <1 mg/mL 104 mg/mL <1 mg/mL
S1528 LY2811376 <1 mg/mL 16 mg/mL 64 mg/mL
S4261 EUK 134 13 mg/mL 83 mg/mL <1 mg/mL
Catalog No. Information Product Use Citations Product Validations
S2215

DAPT (GSI-IX)

DAPT (GSI-IX) is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells.

S1575

RO4929097

RO4929097 is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2.

S2660

MK-0752

MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2.

S1262

Avagacestat (BMS-708163)

Avagacestat (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2.

S1528

LY2811376

LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.

S4261

EUK 134

EUK 134, a synthetic superoxide dismutase (SOD)/catalase mimetic, exhibits potent antioxidant activities, and inhibits the formation of β-amyloid and related amyloid fibril.